JPWO2021064050A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021064050A5
JPWO2021064050A5 JP2022520197A JP2022520197A JPWO2021064050A5 JP WO2021064050 A5 JPWO2021064050 A5 JP WO2021064050A5 JP 2022520197 A JP2022520197 A JP 2022520197A JP 2022520197 A JP2022520197 A JP 2022520197A JP WO2021064050 A5 JPWO2021064050 A5 JP WO2021064050A5
Authority
JP
Japan
Prior art keywords
seq
lpxa
bordetella pertussis
protein
recombinant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022520197A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022550560A (ja
Publication date
Priority claimed from EP19200878.7A external-priority patent/EP3799884A1/en
Application filed filed Critical
Publication of JP2022550560A publication Critical patent/JP2022550560A/ja
Publication of JPWO2021064050A5 publication Critical patent/JPWO2021064050A5/ja
Pending legal-status Critical Current

Links

JP2022520197A 2019-10-01 2020-09-30 免疫原性組成物 Pending JP2022550560A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19200878.7A EP3799884A1 (en) 2019-10-01 2019-10-01 Immunogenic compositions
EP19200878.7 2019-10-01
PCT/EP2020/077416 WO2021064050A1 (en) 2019-10-01 2020-09-30 Immunogenic compositions

Publications (2)

Publication Number Publication Date
JP2022550560A JP2022550560A (ja) 2022-12-02
JPWO2021064050A5 true JPWO2021064050A5 (es) 2023-09-27

Family

ID=68136165

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022520197A Pending JP2022550560A (ja) 2019-10-01 2020-09-30 免疫原性組成物

Country Status (11)

Country Link
US (1) US20220339277A1 (es)
EP (2) EP3799884A1 (es)
JP (1) JP2022550560A (es)
KR (1) KR20220070279A (es)
CN (1) CN114502193A (es)
AU (1) AU2020358775A1 (es)
BR (1) BR112022005345A2 (es)
CA (1) CA3156017A1 (es)
IL (1) IL291559A (es)
MX (1) MX2022003871A (es)
WO (1) WO2021064050A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202211033D0 (en) 2022-07-28 2022-09-14 Glaxosmithkline Biologicals Sa Purification process
CN117417419B (zh) * 2023-01-10 2024-04-19 康希诺生物股份公司 一种百日咳毒素脱毒方法及无细胞百白破联合疫苗

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR5388E (fr) 1905-06-08 1906-03-27 Jean Eugene Gabillon Radiateur à grand pouvoir refroidissant pour automobiles
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
ES2078258T3 (es) 1989-04-28 1995-12-16 Sclavo Spa Mutantes de toxina pertussica, cepas de bordetella capaces de producir tales mutantes y su uso en el desarrollo de vacunas antipertussicas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
ES2143716T3 (es) 1992-06-25 2000-05-16 Smithkline Beecham Biolog Composicion de vacuna que contiene adyuvantes.
JP3828145B2 (ja) 1993-09-22 2006-10-04 ヘンリー エム.ジャクソン ファウンデイション フォー ザ アドバンスメント オブ ミリタリー メディスン 免疫原性構成物の製造のための新規シアン化試薬を使った可溶性炭水化物の活性化方法
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP1167377B2 (en) 1994-07-15 2012-08-08 University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
CZ390297A3 (cs) 1995-06-07 1998-05-13 Smithkline Beecham Biologicals S. A. Kombinovaná vakcína
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
AU755462B2 (en) * 1997-08-21 2002-12-12 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezonheid En Cultuur Novel mutants of gram negative mucosal bacteria and application thereof in vaccines
EP1109576B1 (en) 1998-08-19 2009-10-21 Baxter Healthcare SA Immunogenic beta-propionamido-linked polysaccharide protein conjugate useful as a vaccine produced using an n-acryloylated polysaccharide
ES2298269T3 (es) 2000-09-26 2008-05-16 Idera Pharmaceuticals, Inc. Modulacion de la actividad inmunoestimulante de analogos oligonucleotidicos inmunoestimulantes mediante cambios quimicos posicionales.
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
WO2003050782A1 (fr) 2001-12-12 2003-06-19 Hogakukan Co., Ltd. Systeme de definition d'exercices
GB0202901D0 (en) 2002-02-07 2002-03-27 Glaxosmithkline Biolog Sa Novel vaccine
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0424092D0 (en) * 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0522765D0 (en) 2005-11-08 2005-12-14 Chiron Srl Combination vaccine manufacture
MX2009002560A (es) 2006-09-07 2009-03-20 Glaxosmithkline Biolog Sa Vacuna.
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
EP2820133B1 (en) 2012-02-28 2017-08-02 The Board of Regents of The University of Texas System Synthetic lipid biology for combinatorial engineering of endotoxin
PL404247A1 (pl) * 2013-06-07 2014-12-08 Wrocławskie Centrum Badań Eit + Spółka Z Ograniczoną Odpowiedzialnością Koniugat oligocukru LOS Bordetella pertussis i toksyny krztuśca i jego zastosowanie w profilaktyce i leczeniu zakażeń wywoływanych przez Bordetella pertussis
US10420833B2 (en) 2014-05-19 2019-09-24 Board Of Regents, The University Of Texas System Combinatorial platform for the display of surface adjuvants and antigens
SG11201811350QA (en) 2016-07-28 2019-01-30 Max Planck Gesellschaft Stable hydrolysis-resistant synthetic polyribosylribitolphosphate derivatives as vaccines against haemophilus influenzae type b
EP3596110B1 (en) 2017-03-13 2024-09-04 Intravacc B.V. Bordetella vaccines comprising lps with reduced reactogenicity
KR20200136361A (ko) * 2017-12-04 2020-12-07 드 슈타트 데르 네덜란덴, 베르테겐부어디그트 두어 드 미니스터 반 베이웨이에스, 미니스테리 반 폭스겐트존하이트, 벨지인 엔 스포츠 외막 소포의 생성을 위한 개선된 방법

Similar Documents

Publication Publication Date Title
Ellis New technologies for making vaccines
US6821521B1 (en) Multicomponent meningococcal vaccine
ES2370885T3 (es) Electroporación de mycobacterium y sobreexpresión de antígenos en micobacterias.
ES2821830T3 (es) Cepas de Bordetella vivas atenuadas como vacuna de dosis única contra la tos ferina
US7829104B2 (en) Electroporation of Mycobacterium and overexpression of antigens in mycobacteria
JP2011168611A (ja) 髄膜炎菌類タンパク質nmb1870のドメインおよびエピトープ
PT1076662E (pt) Proteínas transportadoras de poli-epítopos
EP2214840A1 (en) Compositions and methods of enhancing immune responses to flagellated bacterium
OA11940A (en) Attenuated microorganisms for the treatment of infection.
US10967045B2 (en) Multicomponent meningococcal vaccine
WO1989005856A1 (en) Vaccines
IL100010A0 (en) Avirulent strain of salmonella typhi,its preparation and vaccines containing it
US6660261B1 (en) Bordetella strain expressing the FHA hybrid, liposomes and vaccines
JPWO2021064050A5 (es)
FR2840319A1 (fr) Souches de bordetella rendues deficientes par attenuation genetique
US20060115494A1 (en) Recombinant BCG strains with attenuated immunosuppressive properties
JP5547657B2 (ja) パスツレラ・ムルトシダ(P.multocida)のfur細胞およびその外膜タンパク質の抽出物によるパスツレラ・ムルトシダ(Pasteurellamultocida)に対する異種性の防御
US6770275B1 (en) Live attenuated RTC-producing bacteria of the family
Rappuoli et al. New vaccines against bacterial toxins
OA12130A (en) Attenuated microorganisms for the treatment of infection.
JPH05503628A (ja) 新規なワクチン
AU2009273128A1 (en) Constructing a DNA chimera for vaccine development against Leishmaniasis and tuberculosis
Schild et al. Vaccines: Past, present and future
Dougan Genetics as a route toward mucosal vaccine development
WO2022049222A1 (en) Ompa mutations enhance omv production in bordetella pertussis